SECsense Logo
<!-- Icon from Material Symbols by Google - https://github.com/google/material-design-icons/blob/master/LICENSE -->Back to Posts

Neumora Therapeutics 8-K Report: Key Developments on January 2, 2025

$NMRA
8-K
Filed on: 2025-01-02
View Source
Neumora TherapeuticsbiotechnologyNASDAQ NMRA8-K filingfinancial reporting
Neumora Therapeutics 8-K Report: Key Developments on January 2, 2025

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

  1. Entity Information:
  • Company Name: Neumora Therapeutics, Inc.
  • Address: 490 Arsenal Way, Suite 200, Watertown, MA 02472
  • Phone Number: (857) 760-0900
  • CIK Code: 0001885522
  • SEC Central Index Key (CIK): This unique identifier is essential for tracking the company's filings with the SEC.
  1. Filing Type:
  • Form Type: 8-K
  • The 8-K form is used to report major events that shareholders should know about. This could include significant corporate changes, acquisitions, or other important developments.
  1. Reporting Period:
  • Report Date: January 2, 2025
  • The report is for a single day, indicating that it may pertain to an immediate event or announcement relevant to that date.
  1. Stock Information:
  • Common Stock Par Value: $0.0001 per share
  • Ticker Symbol: NMRA
  • Exchange: NASDAQ
  • This indicates that the company is publicly traded, and the stock is listed on the NASDAQ exchange.
  1. Financial Reporting Standards:
  • The report adheres to XBRL (eXtensible Business Reporting Language) guidelines, which is commonly used for financial reporting to enhance the transparency and accessibility of financial data.

Insights:

  • The filing of an 8-K suggests that Neumora Therapeutics may have had a significant event or announcement on January 2, 2025. Investors and stakeholders should look for additional details in this filing to understand the implications of this event.
  • As a biotechnology company (inferred from the name), Neumora Therapeutics may be involved in research and development activities that could impact its stock performance and investor interest.
  • The par value of the common stock being very low ($0.0001) may indicate a startup or early-stage company, which could be in a growth phase or seeking further investment.

This information will help stakeholders gauge the company's current status and any actions they may need to take in response to this report.

You May Also Like